Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avecho BiotechnologyASX:AVE Equity-to-Asset is 0.23 as of Jun. 2026, which is 73% below its 10-year median of 0.85. The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Avecho Biotechnology ranks worse than 80.92% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Avecho Biotechnology's Total Stockholders Equity for the quarter that ended in Jun. 2026 was A$1.91 Mil. Avecho Biotechnology's Total Assets for the quarter that ended in Jun. 2026 was A$8.41 Mil.
Therefore, Avecho Biotechnology's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.23.
The historical rank and industry rank for Avecho Biotechnology's Equity-to-Asset or its related term are showing as below:
ASX:AVE'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12 Med: 0.85 Max: 1.34
Current: 0.23
During the past 13 years, the highest Equity to Asset Ratio of Avecho Biotechnology was 1.34. The lowest was 0.12. And the median was 0.85.
ASX:AVE's Equity-to-Asset is ranked worse than 80.92% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs ASX:AVE: 0.23
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Avecho Biotechnology Equity-to-Asset Related Terms
Avecho Biotechnology Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVE vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Avecho Biotechnology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Avecho Biotechnology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avecho Biotechnology (ASX:AVE) has a Equity-to-Asset of 0.23 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avecho Biotechnology and its competitors. This is 73% below median its historical median of 0.85. Over the past decade, Avecho Biotechnology's Equity-to-Asset has ranged from 0.12 to 1.34. According to the industry distribution chart, Avecho Biotechnology ranks #1145 out of 1415 companies in the Biotechnology industry, placing it in the top 80.9%.
Is Avecho Biotechnology's Equity-to-Asset too high?
Avecho Biotechnology's current Equity-to-Asset of 0.23 is 73% below median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 1.34. The Biotechnology industry median Equity-to-Asset is 0.68. Avecho Biotechnology's value of 0.23 is 66.2% below this industry median. Based on the distribution chart, Avecho Biotechnology ranks #1145 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Avecho Biotechnology's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #1145 out of 1415 companies for Equity-to-Asset. This places Avecho Biotechnology in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Avecho Biotechnology's value of 0.23 is 66.2% below this benchmark. Historically, Avecho Biotechnology's own Equity-to-Asset has ranged from 0.12 to 1.34 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.68, Avecho Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avecho Biotechnology's current Equity-to-Asset of 0.23 is 66.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avecho Biotechnology and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avecho Biotechnology's current Equity-to-Asset is 0.23, which is 73% below median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Equity-to-Asset of 0.23. The current Equity-to-Asset is 0.23, which is 73% below median its 10-year median of 0.85 and 66.2% below the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Equity-to-Asset is 0.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 
